Table 4.

Therapeutic efficacy of azithromycin and NB-UVB at EOS within patients with recent streptococcal infection at EOS

Therapeutic efficacy at EOS		Azithromycin	NB-UVB	p value
		Positive recent streptococcal infection (n = 12)	Positive recent streptococcal infection (n = 7)
Rash as a whole	Complete response	2 (16.67%)	6 (85.7%)	0.106
	Very-good response	5 (41.67%)	1 (14.3%)
	Good response	3 (25%)	0
	Poor response	2 (16.67%)	0

Therapeutic efficacy at EOS		Positive recent streptococcal infection (n = 12)	Positive recent streptococcal infection (n = 7)	p value
Erythematous Papules	Complete response	7 (58.3%)	6 (85.7%)	1
	Very-good response	4 (33.3%)	0
	Good response	0	1 (14.3%)
	Poor response	1 (8.3%)	0

Therapeutic efficacy at EOS		Positive recent streptococcal infection (n = 10)	Positive recent streptococcal infection (n = 7)	p value
Hypopigmented Lesions	Complete response	1 (10%)	7 (100%)	0.01*
	Very-good response	2 (20%)	0
	Good response	3 (30%)	0
	Poor response	4 (40%)	0

Percent reduction in the extent of rash and extent of rash at EOS	Positive recent streptococcal infection (n = 11)	Positive recent streptococcal infection (n = 7)	p value
Percent reduction in the extent of the rash as a whole (mean ± SD)	76.21 ± 13.65	93.36 ± 9.37	0.005*
Extent of the rash as a whole at EOS (% body surface) (mean ± SD)	5.5 ± 5.14	0.97 ± 1.4	0.034*
Percent reduction in the extent of erythematous papules (mean ± SD)	89.01 ± 10.38	90.12 ± 13.21	0.853
Extent of the erythematous papules at EOS (% body surface) (mean ± SD)	1.8 ± 3.57	0.85 ± 1.4	0.513
Percent reduction in the extent of hypopigmented lesions (mean ± SD)	46.9 ± 31.99	97.97 ± 3.57	0.001*

*p value < 0.05 is significant